Xtan­di fails a com­bo study, block­ing a path to con­tin­ued use for Pfiz­er, Astel­las

One of the stud­ies on the prostate can­cer drug Xtan­di that Pfiz­er in­her­it­ed in its $14 bil­lion buy­out of Medi­va­tion has failed to de­liv­er.

The phar­ma gi­ant and its part­ners at Astel­las say that Xtan­di com­bined with J&J’s ri­val Zyti­ga and the steroid pred­nisone failed to bend the curve on pro­gres­sion-free sur­vival for chemo-naive pa­tients whose dis­ease had pro­gressed fol­low­ing treat­ment with Xtan­di, com­pared with a group of pa­tients treat­ed with Zyti­ga and pred­nisone alone. The in­ves­ti­ga­tors had been look­ing for a ra­tio­nale to con­tin­ue treat­ment with Xtan­di, which would have ex­pand­ed its block­buster mar­ket even fur­ther.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.